Posted by Michael Wonder on 24 Mar 2025
CStone submits application to the EMA for new indication of sugemalimab in stage III non-small cell lung cancer
23 March 2025 - CStone Pharmaceuticals today announced the submission of a type II variation application to the EMA for sugemalimab.
The application seeks approval for the treatment of patients with unresectable stage III non-small cell lung cancer who have not progressed following concurrent or sequential platinum-based chemoradiotherapy.
